Ventilator-Associated Pneumonia Clinical Trial
Official title:
Comparison of Endotracheal Tube With Subglottic Suction Drainage With Standard Endotracheal Tube in the Incidence of Airway Colonization and Ventilator Associated Pneumonia
Ventilator Associated Pneumonia (VAP) is associated with increased hospitalisation, increased health care cost and high morbidity and mortality. The incidence of VAP increases with duration of mechanical ventilation. There is limited data especially from India on the incidence of VAP and also the role of subglottic aspiration in its prevention. The aim of this study is to determine the role of subglottic suction in the incidence of VAP.
Patients will be enrolled following inclusion-exclusion criteria
- Base line clinical and laboratory data will be recorded in a pre designed proforma.
- Endotracheal aspirate will be taken at the time of enrollment and day3, day5, day7 and
then weekly till patient is on mechanical ventilation.
Data collection
For each patient following data will be recorded as per the proforma.
During Hospitalization
All eligible patients will be carefully followed up for signs of VAP during hospitalization.
Apart from clinical examination, regular recording of body temperature, observance of
tracheal aspirate appearance, leukocyte counts and chest radiograph will be done.
VAP Diagnosis: Based on American College of Chest Physicians (ACCP) criteria:
An association of a new or progressive consolidation on chest radiograph Plus at least two of
the following variables
- fever > 38 degree
- leucocytosis ( > 12000) or leucopenia ( <4000)
- purulent secretions
At VAP Diagnosis
Patients who diagnosed as cases VAP, based on the above criteria.
Non-bronchoscopic bronchoalveolar lavage (BAL) will be done for microbiological sampling. In
patients where clinically indicated, Flexible bronchoscopy and Bronchoalveolar lavage,
sampling will be done. At the time of VAP diagnosis blood culture and urine culture, will
also be sent.
Sample Collection
Endotracheal aspiration
A sterile 22 inch, 12 French suction catheter with a mucus extractor will be introduced at
least 30 cm and minimum of 5ml sample will be collected. Endotracheal aspirate cultures will
be examined semi quantitatively. Bacterial and antibiotic susceptibility tests will be
performed.
Non bronchoscopic protected BAL
Specimen will be collected by sputum suction trap. A 47-48 cm sterile suction catheter of
16fr will be inserted through endotracheal tube till it meets resistance and will be wedged
there.Then a 50cm long 8fr sterile suction catheter will be passed through it till it meets
resistance and specimen will be taken. 20ml of NS instilled, minimum of 5ml aspirate will be
collected. If aspirate is less than 5 ml it will be repeated.
Bronchoscopic BAL
Consent will be taken from the legal guardian. The patient will receive adequate sedation;
short-acting paralytic agent to prevent coughing during the procedure Will be considered if
necessary. The endotracheal tube will be ≥ 1.5 mm larger than the external diameter of the
flexible bronchoscope. The patients will receive a fraction of inspired oxygen (FiO2) of
100%, and positive-end expiratory pressure will be reduced as much as tolerated. To maximize
ventilation and minimize air trapping, the peak inspiratory flow will be decreased to ≤60
liters/min, the respiratory rate set between 10 and 20 breaths/ min, and the peak inspiratory
pressure alarm increased. The patient will be carefully monitored throughout the procedure.
The sampling area will be chosen based on the location of the infiltrate on chest X-ray.
Microbiological analysis
All the samples were subjected to Gram staining and microscopic examination and were cultured
on sheep blood agar, chocolate agar and MacConkey agar semi quantitatively and 104/ml CFU was
considered significant. Isolated strains were identified by standard microbiological
techniques and the antimicrobial susceptibility testing were performed by disc diffusion
method as per CLSI guidelines. The Gram negative bacilli were tested against the following
antibiotics:amikacin, amoxicillin-clavulanate, cefotaxime, ceftazidime, ciprofloxacin,
cefaperazone-sulbactam, meropenem ,imipenem, netilimicin, Piperacillin-tazobactum.
Additionally colistin and ertapenem will be tested when appropriate. Gram positive organisms
will be tested for amikacin, netilmicin, cotrimoxazole, ceftazidime,
ciprofloxacin,cefoperazone-sulbactam, penicillin, linezolid, erythromycin, vancomycin and
teicoplanin
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01406951 -
Diagnostic Value of sTREM-1 and PCT Level as Well as CPIS Score for Ventilator-Associated Pneumonia Among ICU Sepsis Patients
|
N/A | |
Completed |
NCT00893763 -
Strategies To Prevent Pneumonia 2 (SToPP2)
|
Phase 2 | |
Recruiting |
NCT03581370 -
Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients With Ventilator Associated-pneumonia
|
Phase 3 | |
Completed |
NCT02070757 -
Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)
|
Phase 3 | |
Completed |
NCT03348579 -
Hospital-acquired Pneumonia in Intensive Care Unit
|
||
Completed |
NCT04242706 -
VITAL - VAP Prevention by BIP (Bactiguard Infection Protection) ETT Evac in Belgian ICUs
|
Phase 4 | |
Recruiting |
NCT05589727 -
Application of Ventilator-Associated Events (VAE) in Ventilator-Associated Pneumonia (VAP) Notified in Brazil
|
||
Not yet recruiting |
NCT06168734 -
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
|
Phase 3 | |
Completed |
NCT02515448 -
A Pharmacokinetic-pharmacodynamic Dose Comparison Study of 8 mg/kg of Inhaled or Parenteral Gentamicin in 12 Mechanically Ventilated Critically Ill Patients Treated for Ventilator-associated Pneumonia
|
Phase 1 | |
Completed |
NCT01972425 -
Biomarker-based Exclusion of VAP for Improved Antibiotic Stewardship
|
N/A | |
Completed |
NCT02838160 -
Effectiveness of Different Educational Strategies on the KAP, Psychological and Clinical Outcomes
|
N/A | |
Completed |
NCT01467648 -
The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia
|
Phase 4 | |
Completed |
NCT00364299 -
Prevention of Ventilator-Associated Pneumonia by Automatic Control of the Tracheal Tube Cuff Pressure
|
N/A | |
Not yet recruiting |
NCT03018431 -
CT Scan and Lung Ultrasonography to Improve Diagnostic of Ventilation Acquired Pneumonia in ICU
|
N/A | |
Completed |
NCT02515617 -
Medico-economic Study of the Subglottic Secretions Drainage in Prevention of Ventilator-associated Pneumonia (DEMETER)
|
N/A | |
Completed |
NCT02583308 -
Impact of the Subglottic Secretions Drainage on the Tracheal Secretions Colonisation
|
N/A | |
Completed |
NCT02585180 -
Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia
|
N/A | |
Recruiting |
NCT01546974 -
Ventilator-associated Pneumonia (VAP) and Humidification System
|
Phase 4 | |
Completed |
NCT02060045 -
Prevention Ventilator Associated Pneumonia
|
N/A | |
Terminated |
NCT00543608 -
Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia
|
Phase 2 |